Integrative approaches targeting neurological and immune pathways may help break the itch–scratch cycle in atopic dermatitis, improving pruritus, stress, sleep, and patient outcomes.

Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with ...

Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical trial titled ‘A PHASE 1, ...

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3b clinical ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

With most families turning to OTC meds before the first office visit, pediatric and primary care clinicians are key ...

We have front row seats these days as a new country literally appears before our eyes. Call it what you want. I’m going with ...

Individuals presenting with one of several immune-mediated skin diseases may also have a substantially higher risk for keratoconus (KC), according to a large multicenter investigation published in ...